AI for Pharma Growth
E192: Building Biotech: What It Takes to Lead a Public Life Sciences Company
AI for Pharma Growth
•November 19, 2025•29 min
0
AI for Pharma Growth•Nov 19, 2025
Why It Matters
Integrating AI into biotech shortens development timelines, cuts costs, and opens new capital channels, fundamentally reshaping cancer therapy pipelines and market dynamics.
Key Takeaways
- •Wall Street experience informs public biotech strategy
- •AI-driven NLP identifies drug development gaps
- •Single-cell analysis accelerates gamma delta T cell discovery
- •AI optimizes cell therapy manufacturing and supply chain
- •TikTok reshapes biotech investor outreach
Pulse Analysis
Artificial intelligence is rapidly becoming a cornerstone of modern biotech, and IN8 Bio exemplifies this shift. By applying machine‑learning models to RNA‑seq and single‑cell datasets, the company uncovers novel gamma‑delta T‑cell targets that traditional pipelines often miss. This AI‑driven discovery not only speeds pre‑clinical research but also enhances the precision of candidate selection, positioning IN8 Bio at the forefront of next‑generation immunotherapies. The convergence of computational biology and AI is redefining how biotech firms approach complex disease mechanisms, creating a competitive edge in a crowded market.
Beyond discovery, AI is transforming the manufacturing landscape for cell therapies. Advanced algorithms and large language models analyze production data in real time, identifying bottlenecks and optimizing bioreactor conditions to improve yield while reducing waste. This automation enables scalable, cost‑effective manufacturing—a critical factor for public biotech companies facing investor scrutiny. Moreover, AI tools assist in maintaining FDA compliance by continuously monitoring quality metrics and generating documentation, thereby streamlining regulatory pathways and accelerating time‑to‑market.
The ripple effects extend to capital markets and stakeholder engagement. As younger investors turn to platforms like TikTok for biotech insights, companies such as IN8 Bio are tailoring their communication strategies to algorithmic feeds, leveraging short‑form video to convey scientific breakthroughs and financial milestones. This digital outreach, combined with transparent AI‑enabled data sharing, builds investor confidence and broadens funding sources. Ultimately, the integration of AI across discovery, production, and market positioning fuels IN8 Bio’s mission of "Cancer Zero," illustrating how technology can drive both scientific and commercial success in the life‑sciences sector.
Episode Description
In this episode, we sit down with Dr. William Ho, President, CEO, and Co-Founder of IN8 Bio — a pioneering biotech company developing next-generation Gamma Delta T cell therapies for both solid and hematologic cancers.
From Wall Street to the biotech lab, Dr. Ho shares his remarkable journey and how he’s leveraging artificial intelligence, data analytics, and computational biology to reshape cell therapy development, manufacturing, and scalability.
Discover how AI is transforming every stage of biotech — from drug discovery and clinical trial optimization to manufacturing automation and investor relations — and why Dr. Ho believes it’s key to achieving IN8 Bio’s mission of Cancer Zero.
Key Highlights
From finance to pharma: How Dr. Ho’s Wall Street experience shaped his approach to building a public biotech company.
AI in biotech innovation: Real-world examples of using natural language processing and machine learning to uncover drug-development gaps.
Data-driven discovery: How IN8 Bio uses AI, RNA Seq, and single-cell analysis to advance Gamma Delta T cell therapies.
Smarter manufacturing: The role of AI and LLMs in optimizing cell-therapy production, reducing costs, and managing global supply chains.
Regulatory readiness: How biotech companies can navigate FDA compliance while integrating AI tools.
Capital markets & biotech: Why the next generation of investors discover biotech companies on TikTok — and how IN8 Bio adapts to the algorithmic market.
Mission Cancer Zero: How AI will help achieve a future where no patient dies of cancer.
About the Podcast
AI for Pharma Growth is a podcast focused on exploring how artificial intelligence can revolutionise healthcare by addressing disparities and creating equitable systems. Join us as we unpack groundbreaking technologies, real-world applications, and expert insights to inspire a healthier, more equitable future.
This show brings together leading experts and changemakers to demystify AI and show how it’s being used to transform healthcare. Whether you're in the medical field, technology sector, or just curious about AI’s role in social good, this podcast offers valuable insights.
AI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr. Andree Bates created to help organisations understand how the use of AI based technologies can easily save them time and grow their brands and business. This show blends deep experience in the sector with demystifying AI for all pharma people, from start up biotech right through to Big Pharma. In this podcast Dr Andree will teach you the tried and true secrets to building a pharma company using AI that anyone can use, at any budget.
As the author of many peer-reviewed journals and having addressed over 500 industry conferences across the globe, Dr Andree Bates uses her obsession with all things AI and futuretech to help you to navigate through the, sometimes confusing but, magical world of AI powered tools to grow pharma businesses.
This podcast features many experts who have developed powerful AI powered tools that are the secret behind some time saving and supercharged revenue generating business results. Those who share their stories and expertise show how AI can be applied to sales, marketing, production, social media, psychology, customer insights and so much more.
Dr. Andree Bates LinkedIn | Facebook |<a href="https://x.com/TheAmeliaAI" rel="noopener noreferrer"...
Show Notes
0
Comments
Want to join the conversation?
Loading comments...